SEC Tracker
Get the app

Orchestra BioMed Holdings OBIO

Orchestra BioMed Holdings reports $18.75 million net loss

Orchestra BioMed Holdings (OBIO) filed a 10-Q with the SEC on Nov 10, 2026, 4:05 pm ET. Source: the filing on SEC EDGAR.

Form
10-Q
Filed
Importance
Notable
  1. Revenue: $91,000 for the three months ended Sep 30, 2026
  2. Net loss: $18.75 million for the three months ended Sep 30, 2026
  3. Diluted EPS: -$0.30 for the three months ended Sep 30, 2026
  4. Cash and equivalents: $27.76 million at Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Get the appView on EDGAR

Get an email when Orchestra BioMed Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

What changed since last quarter

No new risk factors or legal mentions.

Compared with the 10-Q for the period ended Jun 30, 2026.

Key numbers from the XBRL in this filing and the previous one.
This filingPreviousChange vs prior 10-Q
Revenue$91K$88K+3.4%
Operating income and margin−$23.3M · -25600%−$22.36M · -25404.5%−4.2%, margin −195.5 pts
Net income−$18.75M−$23.76M+21%
Operating cash flow−$19.54M−$19.33M−1.1%
Cash$27.76M$20.47M+36%

Data on this page was fetched . The filing on SEC.gov is the record.